Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Vivoryon Therapeutics has announced promising results from its Phase 2b study of varoglutamstat, showing significant improvement in kidney function, particularly among diabetic patients. The drug demonstrated an excellent safety profile and may offer a new treatment approach for diabetic kidney disease and other kidney disorders. The company plans further studies to confirm these effects.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.
